13F-HR filed by NOVO HOLDINGS A/S
NOVO HOLDINGS A/S filed this 13F-HR for the quarter ended 2026-03-31, filed 2026-05-15, with 22 holding rows worth $1,234,214,742.
- Accession
- 0001388325-26-000026
- Filer
- CIK 1388325
- Filed
- 2026-05-15
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q1 2026
A holdings report, 22 entries on the cover page, a total value of $1,234,214,742 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,234,214,742 with VALUE read as dollars as filed, 13F file number 028-16231. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| EDGEWISE THERAPEUTICS INC | 28036F105 | COM | 5,350,000 | $168,525,000 | dollars as filed | |
| BROOKFIELD CORP CL A LTD VT SH | 11271J107 | Stock | 3,496,245 | $141,493,035 | dollars as filed | |
| ASMLHLDGNVFSPONSOREDADR1ADRREPS1ORDSHS | N07059210 | STOK | 94,946 | $125,407,525 | dollars as filed | |
| MIRUM PHARMACEUTICALS INC | 604749101 | COM | 1,325,000 | $122,403,500 | dollars as filed | |
| MAPLIGHT THERAPEUTICS INC | 56565P103 | COMMON STOCK | 3,686,622 | $74,949,025 | dollars as filed | |
| Salesforce.com, Inc | 79466L302 | COM | 393,187 | $73,396,217 | dollars as filed | |
| CRINETICS PHARMACEUTICALS INC COM | 22663K107 | Stock | 1,550,000 | $56,296,000 | dollars as filed | |
| ENLIVEN THERAPEUTICS INC COM | 29337E102 | Stock | 1,280,000 | $50,176,000 | dollars as filed | |
| VAXCYTE INC COM | 92243G108 | Stock | 860,000 | $49,974,600 | dollars as filed | |
| PHARVARIS NV | N69605108 | COMMON STOCK | 1,750,000 | $49,437,500 | dollars as filed | |
| ARRIVENT BIOPHARMA INC | 04272N102 | COM | 1,942,142 | $44,805,216 | dollars as filed | |
| VIRIDIAN THERAPEUTICS INC | 92790C104 | COM | 2,000,000 | $39,120,000 | dollars as filed | |
| CELLDEX THERAPEUTICS INC NEW | 15117B202 | COM NEW | 1,200,000 | $38,064,000 | dollars as filed | |
| APOGEE THERAPEUTICS INC COM | 03770N101 | Stock | 450,000 | $37,876,500 | dollars as filed | |
| BIOMARIN PHARMACEUTICAL INC | 09061G101 | COM | 660,000 | $37,283,400 | dollars as filed | |
| 4D MOLECULAR THERAPEUTICS INC COM | 35104E100 | Stock | 3,650,737 | $33,988,361 | dollars as filed | |
| ALIBABA GROUP HLDG LTD | 01609W102 | SPONSORED ADS | 257,327 | $32,284,245 | dollars as filed | |
| XENON PHARMACEUTICALS INC COM | 98420N105 | Stock | 485,438 | $28,228,220 | dollars as filed | |
| BRIDGEBIO ONCOLOGY THERAPEUT | 107924102 | COM NEW | 2,185,923 | $19,564,011 | dollars as filed | |
| Valneva SE ADR | 92025Y103 | COM | 1,057,421 | $6,608,881 | dollars as filed | |
| LANZATECH GLOBAL INC | 51655R200 | CMN | 158,148 | $2,531,949 | dollars as filed | |
| MARQETA INC | 57142B104 | CLASS A COM | 441,558 | $1,801,557 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001388325-26-000026 | this filing | 2026-05-15 | acceptance time not in the bulk data set |